RUBOMITSIN (Rubomycinum; synonym: Daunomycin, Daunoblastin, Daunorubicin, Rubidomycine etc.; joint venture. B) — the antineoplastic antibiotic allocated from culture of a radiant fungus of Actinomyces coeruleorubidus and relating to group of anthracycline antibiotics. The hydrochloride of a glycoside consisting of агликона-4-метокси-6,7,9,11-тетраокси-9-ацето-7,8,9,10-тетрагидротетраценхинона and аминосахара-2,2,6-тридезокси-3-амино-L-ликсозы:
Crystal powder or porous mass of red color. It is hygroscopic, we will well dissolve in water, alcohol and physiological solution. The river has antibacterial and antineoplastic activity. It blocks synthesis nucleinic to - t, in particular DNA. The main amount of the administered drug contacts fabrics. No more than 10% of R. are removed during 24 hours with bile.
Apply River for treatment of an acute leukosis, a horionepitelioma of a uterus, lympho-and reticulosarcomas, rhabdomyosarcomas and neuroblastomas at children. Contraindications — a leukopenia lower than 4000 and thrombocytopenia lower than 150 000 in 1 mkl blood (except for leukoses), sharp exhaustion, serious associated diseases of heart and liver.
Treatment is usually carried out by cycles. At first appoint two cycles lasting 5 days with a break between them 7 — 10 days. The drug during a cycle is administered daily intravenously on 0,8 — 1,0zhgna 1 kg of the weight (weight) of the patient. At further repetition of cycles of treatment intervals between administrations of drug usually increase to 48 hours, duration of a cycle to 10 days, and breaks between cycles to 2 — 3 weeks
Besides, there are two modes of treatment of R.: at intermittent operation the raised single doses of drug (1,5 — 1,7 mg/kg) enter with an interval of 5 days, a course dose of 250 — 500 mg; at the fractional and extended mode causing smaller intoxication daily intravenously enter 0,25 — 0,3 mg/kg of R., a course dose of 300 — 500 mg. Usually total dose makes 15 mg/kg and above, but no more than 25 mg! kg. At patients with an acute leukosis to lay down. the effect is shown at once after the first injection of drug; at treatment of solid tumors, in particular horionepitelioma of a uterus, objective improvement occurs after the second cycle and accrues at the subsequent courses. The river can be used in a combination with other antineoplastic means and radiation therapy.
The most characteristic side effect oppression of function of a hemopoiesis is; the leukopenia (granulocytopenia) is more often observed, is more rare — thrombocytopenia. At overdose a number of patients has an anorexia, nausea, sometimes vomiting, diarrhea, an abnormal liver function, a headache. For decrease in the specified toxic phenomena purpose of Dimedrol is recommended, at vomiting — aminazine, this-perazina, Frenolonum. At the expressed dispeptic phenomena reduce a single dose of R., increase intervals between injections of drug. At fungal infections of a mucous membrane of an oral cavity appoint nystatin, Dekaminum. At prolonged treatment and high total doses of an antibiotic the cardiotoxic effect therefore the total dose of R. shall not exceed 25 mg/kg is possible.
After radiation therapy and treatment other antineoplastic means of R. appoint not earlier than in 2 weeks after recovery of normal indicators of blood.
Release in bottles on 20 and 40 mg (in terms of a chemically pure hydrochloride of a rubomitsin). Before the use contents of bottles are dissolved in 10 ml of isotonic solution of sodium of chloride. Store in the dry place protected from light at the room temperature.
See also Antineoplastic means .
Bibliography: Perevodchikova N. I. Clinical chemotherapy of tumoral diseases, page 87, M., 1976; Antineoplastic antibiotics Olivomycinum, Bruneomycinum, rubomitsin and their use in clinic, under the editorship of G. F. Gauz, page 225, M., 1971; Toloknov B. O. Rubomitsin in treatment of trophoblastic tumors, Vopr. onkol., t. 19, No. 2, page 23, 1973; Hvatova N. V. Rubomitsin in therapies of acute leukoses, Antibiotics, t. 15, No. 12, page 1108, 1970; Chemotherapy of malignant tumors, under the editorship of H. N. Blochina, page 118, 235, M., 1977.
Yu. N. Sokolov.